Recent Press Releases

Allergan Confirms Generic Noxafil(R) Patent Challenge

DUBLIN, Aug. 11, 2015 /PRNewswire/ -- Allergan plc (NYSE: AGN) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking...

Zydus Cadila Q1 Net Profit up by 47%

For the first quarter ended June 30, 2015, Zydus Cadila reported total operating income of Rs. 2,500 crore, up by 22% from Rs. 2,050 crore in the corresponding quarter of the previous year on a...

Orexo: U.S. FDA Approves ZUBSOLV® for Induction of Buprenorphine Maintenance Therapy in Patients Suffering from Opioid Dependence

Orexo: U.S. FDA Approves ZUBSOLV® for Induction of Buprenorphine Maintenance Therapy in Patients Suffering from Opioid Dependence August 11, 2015 02:39 AM Eastern Daylight Time UPPSALA,...

Ludwig N. Hantson, Ph.D., Baxalta Chief Executive Officer and President - 8/10 Call Comments

Ludwig N. Hantson, Ph.D., Chief Executive Officer and President: We are pleased to provide an update on Baxalta's exciting growth prospects, and our continued focus on creating shareholder value....

FDA accepts a Supplemental New Drug Application for review of Brintellix (vortioxetine) clinical trial data that assessed cognitive function in patients with major depressive disorder

FDA accepts a Supplemental New Drug Application for review of Brintellix (vortioxetine) clinical trial data that assessed cognitive function in patients with major depressive disorder Valby, Denmark...

"Roche Continents" fosters innovation in science and art

Students of science and art visit Salzburg Festival to identify sources of inspiration Today, Roche welcomed 100 European university students from 34 countries studying science and art to the...

Cipla announces a new respiratory inhaler: Synchrobreathe (SB), a state-of-the-art breath-actuated inhaler which will bring relief to millions of patients with Obstructive Airway Disease

Innovative respiratory inhaler presented by Cipla at SATS congress India, Mumbai 11 August 2015: Today Cipla, a global pharmaceutical company which uses cutting edge technology and innovation...

CVS Health Research Institute Encourages Reconsideration of Current Cholesterol Management Guidelines as New Class of High-cost Drugs Hit the Market

Guidelines that incorporate specific cholesterol targets would help to determine optimal use of PCSK9 inhibitors and enable effective utilization management WOONSOCKET, R.I., (August 10, 2015)...

Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Acquisition Of Therakos, Inc.

-- Enters into definitive agreement to acquire Therakos, Inc. for $1.325 billion from The Gores Group, LLC - --Transaction expected to be accretive by no less than $0.10 per share to...

Horizon Pharma plc Announces Record Second Quarter 2015 Financial Results

Net Sales of $172.8 Million, up 161 Percent; Adjusted EBITDA of $76.1 Million, up 254 Percent; Adjusted Operating Cash Flow of $129.6 Million; GAAP Operating Cash Flow of $41.6 Million; Confirms...

Taro Provides Results for Quarter Ended June 2015

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Aug. 6, 2015-- Taro Pharmaceutical Industries Ltd.(NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the...

Orexigen and Takeda Announce an Amended and Restated Collaboration Agreement

Partnership Reaffirms Commitment to the Success of CONTRAVE® (naltrexone HCl / bupropion HCl extended-release tablets) SAN DIEGO and DEERFIELD, Ill., Aug. 6, 2015 /PRNewswire/ -- Orexigen...

Depomed Sends Letter to Horizon Pharma

Highlights Horizon's Failure to Make Compelling Proposal Despite Horizon's Stated Willingness to Increase Price and Include Cash Component NEWARK, Calif., Aug. 7, 2015 /PRNewswire/ --...

Novo Nordisk increased operating profit in Danish kroner by 57% in the first six months of 2015 to DKK 26.3 billion

16% local currency operating profit growth adjusted for the NNIT divestment Sales increased by 25% in Danish kroner and by 9% in local currencies to DKK 52.3 billion. Sales of Victoza®...

AMAG Pharmaceuticals Announces Proposed Private Offering of $450 Million of Senior Notes Due 2023

WALTHAM, Mass., Aug. 5, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that it intends, subject to market and other considerations, to offer $450 million aggregate...

Allergan and KYTHERA Announce that Pending Transaction will now be for All-Cash Consideration

DUBLIN and WESTLAKE VILLAGE, Calif., Aug. 5, 2015 /PRNewswire/ -- Allergan plc (NYSE: AGN) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that they have amended and restated...

Endo Divests Non-Core Business Lines from Litha Healthcare Group International Business, Enhancing Focus on Specialty Pharmaceuticals

Strategic divestiture of non-core product lines accelerate the alignment of Litha Healthcare Group around specialty pharmaceuticals DUBLIN, Aug. 5, 2015 /PRNewswire/ -- Endo International plc...

Baxalta Confirms Receipt of Highly Conditional, Unsolicited Proposal from Shire

Same Proposal Rejected Privately on July 10, 2015 · Board Reaffirms its Unanimous Conclusion that Shire's Proposal Significantly Undervalues Baxalta DEERFIELD, Ill., August 4,...

Two Altasciences Executives Named PharmaVOICE 100 Most Inspiring People in the Life-Sciences Industry

LAVAL, Quebec--Altasciences, a provider of top tier customer-tailored early phase clinical trial services, is pleased to announce that Chris Perkin, CEO at Altasciences, and his colleague, Dr. Brad...

Regeneron Reports Second Quarter 2015 Financial and Operating Results

- Second quarter 2015 EYLEA® (aflibercept) Injection global net sales increased 50% to $993 million (consisting of $655 million in the U.S. and $338 million in rest of world(1)) versus second...